Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University,
Nanjing, Jiangsu 210029, China
2.
Department of Thoracic Cardiovascular Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu
221006, China
3.
Department of Orthopaedics, Xuzhou First People's Hospital, Xuzhou, Jiangsu 221006, China
4.
Department of Neurology, Yancheng City No.1 People's Hospital, Yancheng, Jiangsu 224000, China
5.
Research Facility Center for Morphology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
6.
Department of Orthopaedics, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006, China
Funds:
This work was supported by the National Natural
Science Foundation of China (81270173), Jiangsu
government grant to study abroad (JS-2013-246) and
Xuzhou Science and Technology Projects (XZZD-
1329)
Acrylic bone cements are currently the most frequently and extensively used materials in orthopedic implant
treatment. However, adverse effects have been described of acrylic bone cement on the cardiovascular system. In the
present study, we examined the cytotoxicity of bone cement ingredient methyl methacrylate (MMA) to
cardiomyocytes and the potential detoxifying effect of pigment epithelium-derived factor (PEDF) in H9c2 cells.
We found that high concentration of MMA ( > 120 mmol/L) led to necrotic cell death in H9c2 cells. However, MMA
at low concentrations (30-90 mmol/L) caused apoptosis. Pretreatment of PEDF prevented MMA-induced
cytotoxicity. In addition, PEDF enhanced total superoxide dismutase activities, and decreased MMA-induced
production of malonaldehyde. Furthermore, MMA-induced downregulation of Akt activity was suppressed by PEDF.
PEDF also increased the levels of peroxisome proliferator activated receptor gamma (PPARg) and lysophosphatidic
acids (LPA) through PEDF receptor. These results indicated that PEDF inhibited MMA-induced cytotoxicity through
attenuating oxidative stress, activating the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and/or PEDF receptorLPA-PPARg pathways in H9c2 cells. PEDF may be explored as a candidate therapeutic agent for alleviating bone
cement implantation syndrome during orthopedic surgery.